Table 3. Differentially expressed pathways between RA knee and hip FLS.
| IPA pathways | -log (P-value) | Ratio |
|---|---|---|
| Coagulation system | 3.44 | 0.10 |
| Acute phase response signalling | 2.19 | 0.03 |
| Glutamate-dependent acid resistance | 2.03 | 0.50 |
| Hepatic fibrosis/hepatic stellate cell activation | 2.01 | 0.02 |
| IL-6 signalling | 1.78 | 0.03 |
| Protein citrullination | 1.73 | 0.25 |
| Glutamate degradation III (via 4-aminobutyrate) | 1.64 | 0.20 |
| Wnt/Ca+ pathway | 1.58 | 0.04 |
| Gαq signalling | 1.53 | 0.02 |
| Gap junction signalling | 1.52 | 0.02 |
| Tryptophan degradation to 2-amino-3- carboxymuconate semialdehyde | 1.49 | 0.14 |
| Salvage pathways of pyrimidine deoxyribonucleotides | 1.43 | 0.13 |
| Growth hormone signalling | 1.41 | 0.03 |
| Extrinsic prothrombin activation pathway | 1.23 | 0.08 |
| NAD biosynthesis II (from tryptophan) | 1.23 | 0.08 |
| Role of tissue factor in cancer | 1.07 | 0.02 |
| Type I diabetes mellitus signalling | 1.06 | 0.02 |
| Tryptophan degradation III (eukaryotic) | 1.05 | 0.05 |
| Sperm motility | 1.02 | 0.02 |
| Cellular effects of sildenafil | 1.01 | 0.02 |
FLS, fibroblast-like synoviocyte; IPA, Ingenuity Pathway Analysis (see Methods); Ratio, number of DEGs divided by the total number of genes in the pathway; RA, rheumatoid arthritis.